Review



fluorogenic hdac substrate class iia  (BPS Bioscience)


Bioz Verified Symbol BPS Bioscience is a verified supplier
Bioz Manufacturer Symbol BPS Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    BPS Bioscience fluorogenic hdac substrate class iia
    Fluorogenic Hdac Substrate Class Iia, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Fluorogenic+HDAC+class+2a+substrate/pm42966048-513-28-33
    Average 94 stars, based on 25 article reviews
    fluorogenic hdac substrate class iia - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Inhibition:

    Article Title: Dual HDAC/BRD4 inhibitors against cancer
    Article Snippet: Despite much research and undeniable advances, cancer treatment and prevention has remained a major challenge for scientists.. Both genetic and epigenetic changes are involved in the growth and development of cancer complex and multifactorial disease.. Among the possible treatment options, multidrug epigenetic therapy such as the use of dual epigenetic inhibitors, has been a popular option in recent years.

    Article Title: Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition
    Article Snippet: .. A commercially available fluorogenic M pro protease assay kit (BPS Bioscience, San Diego, CA, USA) consisting of a proprietary fluorogenic substrate (emission wavelength at 460 nm), was used to determine inhibition activity in vitro . ..

    Article Title: Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition
    Article Snippet: .. The protease and deubiquitinase inhibition activities of hypericin were determined using commercial PL pro assay kits, consisting of a proprietary fluorogenic substrate at an emission wavelength of 460 nm (BPS Bioscience, San Diego, CA, USA). ..

    Fluorescence:

    Article Title: Dual HDAC/BRD4 inhibitors against cancer
    Article Snippet: Despite much research and undeniable advances, cancer treatment and prevention has remained a major challenge for scientists.. Both genetic and epigenetic changes are involved in the growth and development of cancer complex and multifactorial disease.. Among the possible treatment options, multidrug epigenetic therapy such as the use of dual epigenetic inhibitors, has been a popular option in recent years.

    Activity Assay:

    Article Title: Dual HDAC/BRD4 inhibitors against cancer
    Article Snippet: Despite much research and undeniable advances, cancer treatment and prevention has remained a major challenge for scientists.. Both genetic and epigenetic changes are involved in the growth and development of cancer complex and multifactorial disease.. Among the possible treatment options, multidrug epigenetic therapy such as the use of dual epigenetic inhibitors, has been a popular option in recent years.

    Article Title: Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition
    Article Snippet: .. A commercially available fluorogenic M pro protease assay kit (BPS Bioscience, San Diego, CA, USA) consisting of a proprietary fluorogenic substrate (emission wavelength at 460 nm), was used to determine inhibition activity in vitro . ..

    Article Title: Compositions for and methods of inhibiting SARS-CoV2 infection
    Article Snippet: .. ACE2 Inhibitor Screening Assay An ACE2 inhibitor screening assay kit with fluorogenic substrate (Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA) and adapted to measure the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Article Title: Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro
    Article Snippet: .. An ACE2 Inhibitor screening assay kit with a fluorogenic substrate (Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA) and adapted to measure the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Article Title: The Extracts of Polygonum cuspidatum Root and Rhizome Block the Entry of SARS-CoV-2 Wild-Type and Omicron Pseudotyped Viruses via Inhibition of the S-Protein and 3CL Protease
    Article Snippet: .. The anti-3CL protease activities of the extracts were detected on a fluorogenic substrate with the SensoLyte SARS-CoV-2 3CL Protease Activity assay kit (BPS Bioscience, San Diego, CA, USA), following the instructions from the manufacturer. ..

    Article Title: Aspects of the physiochemical properties of SARS-CoV-2 to prevent S-protein receptor binding using Arabic gum
    Article Snippet: .. An ACE2 Inhibitor Screening Assay Kit with a Fluorogenic Substrate (Catalog #79923) was provided by BPS Bioscience (San Diego, CA), which was modified to evaluate the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Recombinant:

    Article Title: Dual HDAC/BRD4 inhibitors against cancer
    Article Snippet: Despite much research and undeniable advances, cancer treatment and prevention has remained a major challenge for scientists.. Both genetic and epigenetic changes are involved in the growth and development of cancer complex and multifactorial disease.. Among the possible treatment options, multidrug epigenetic therapy such as the use of dual epigenetic inhibitors, has been a popular option in recent years.

    Protease Assay:

    Article Title: Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition
    Article Snippet: .. A commercially available fluorogenic M pro protease assay kit (BPS Bioscience, San Diego, CA, USA) consisting of a proprietary fluorogenic substrate (emission wavelength at 460 nm), was used to determine inhibition activity in vitro . ..

    In Vitro:

    Article Title: Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition
    Article Snippet: .. A commercially available fluorogenic M pro protease assay kit (BPS Bioscience, San Diego, CA, USA) consisting of a proprietary fluorogenic substrate (emission wavelength at 460 nm), was used to determine inhibition activity in vitro . ..

    Screening Assay:

    Article Title: Compositions for and methods of inhibiting SARS-CoV2 infection
    Article Snippet: .. ACE2 Inhibitor Screening Assay An ACE2 inhibitor screening assay kit with fluorogenic substrate (Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA) and adapted to measure the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Article Title: Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro
    Article Snippet: .. An ACE2 Inhibitor screening assay kit with a fluorogenic substrate (Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA) and adapted to measure the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Article Title: Aspects of the physiochemical properties of SARS-CoV-2 to prevent S-protein receptor binding using Arabic gum
    Article Snippet: .. An ACE2 Inhibitor Screening Assay Kit with a Fluorogenic Substrate (Catalog #79923) was provided by BPS Bioscience (San Diego, CA), which was modified to evaluate the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..

    Modification:

    Article Title: Aspects of the physiochemical properties of SARS-CoV-2 to prevent S-protein receptor binding using Arabic gum
    Article Snippet: .. An ACE2 Inhibitor Screening Assay Kit with a Fluorogenic Substrate (Catalog #79923) was provided by BPS Bioscience (San Diego, CA), which was modified to evaluate the exopeptidase activity of ACE2 in the presence and absence of inhibitors. ..



    Similar Products

    94
    R&D Systems plaqav dpa rsssr nh2 fluorogenic peptide substrate iii
    Plaqav Dpa Rsssr Nh2 Fluorogenic Peptide Substrate Iii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Mca-PLAQAV-Dpa-RSSSR-NH2+Fluorogenic+Peptide+Substrate/pm42979410-90-14-27
    Average 94 stars, based on 1 article reviews
    plaqav dpa rsssr nh2 fluorogenic peptide substrate iii - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    BPS Bioscience fluorogenic hdac substrate class iia
    Fluorogenic Hdac Substrate Class Iia, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Fluorogenic+HDAC+class+2a+substrate/pm42966048-513-28-33
    Average 94 stars, based on 1 article reviews
    fluorogenic hdac substrate class iia - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    BPS Bioscience fluorogenic acetylated hdac substrate 3
    Fluorogenic Acetylated Hdac Substrate 3, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Fluorogenic+HDAC+substrate+3/pm42966048-513-11-16
    Average 94 stars, based on 1 article reviews
    fluorogenic acetylated hdac substrate 3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    ImmunoChemistry Technologies fluorogenic magic red cathepsin b substrate
    (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing <t>Cathepsin</t> <t>B</t> activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.
    Fluorogenic Magic Red Cathepsin B Substrate, supplied by ImmunoChemistry Technologies, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Cathepsin+B/bio_rxiv__64898__2026__10__12__758439-449-12-18
    Average 95 stars, based on 1 article reviews
    fluorogenic magic red cathepsin b substrate - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Echelon Biosciences fluorogenic peptide substrate
    (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing <t>Cathepsin</t> <t>B</t> activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.
    Fluorogenic Peptide Substrate, supplied by Echelon Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Ac-VEID-AFC/pm42883722-218-19-22
    Average 94 stars, based on 1 article reviews
    fluorogenic peptide substrate - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    BPS Bioscience fluorogenic peptide substrate
    (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing <t>Cathepsin</t> <t>B</t> activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.
    Fluorogenic Peptide Substrate, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/PLPro+Substrate/10__25259_slash_jksus_15_2026-178-1-11
    Average 93 stars, based on 1 article reviews
    fluorogenic peptide substrate - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology fluorogenic ne substrate meosuc aapv amc
    (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing <t>Cathepsin</t> <t>B</t> activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.
    Fluorogenic Ne Substrate Meosuc Aapv Amc, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/MeOSuc-AAPV-AMC/pmc13574648-86-1-5
    Average 93 stars, based on 1 article reviews
    fluorogenic ne substrate meosuc aapv amc - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    MedChemExpress fluorogenic caspase 1 substrate ac yvad amc
    Pre‐incubation with Pep19‐2.5 inhibits nigericin‐ and MSU crystal‐induced IL‐1β secretion. (A) Primary monocytes were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and then stimulated with 10 µM nigericin or 200 µg/mL MSU crystals for 3 h. Pep19‐2.5 was added 30 min before priming at increasing concentrations ranging from 0.4 to 18 µM. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean ± SEM ( n = 4 biologically independent experiments for nigericin, n = 2 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (B) hMDMs were primed with 1 µg/mL Pam 3 CSK 4 for 4 h and then stimulated with 5 µM nigericin for 2 h. Pep19‐2.5 was added at the indicated concentrations 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimuli‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments). One‐sample t ‐test against 100%. (C) THP‐1 macrophages were primed and stimulated as described in (A). For inhibition experiments, 18 µM Pep19‐2.5 was added 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments for nigericin, n = 3 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (D and E) THP‐1 macrophages were primed and treated with NLRP1 (D) or AIM2 (E) activators. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (F–H) Protein expression of pro‐IL‐1β (F), full‐length (G), and cleaved GSDMD (H) were analyzed by Western blot. Basal, Pam 3 CSK 4 ‐ or nigericin‐induced expression was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (I) THP‐1 macrophages were primed and stimulated after peptide incubation as described in (A). After 1 h of stimulation with nigericin, the medium was removed, and Z‐WEHD buffer was added according to the manufacturer´s protocol. Ac‐YVAD‐CHO control was subtracted, and <t>stimulus‐induced</t> <t>caspase‐1</t> activity was normalized to 100%. Mean ± SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (J) hMDMs from healthy donors were seeded in µ‐Slides VI and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Macrophages were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and stimulated with 10 µM nigericin for 1 h in the presence of fluorophore‐conjugated Rh‐Pep19‐2.5. Active caspase‐1 was stained with the caspase‐1 pseudosubstrate FLICA660‐YVAD‐FMK. Cells were washed and fixed, and nuclei were stained with Hoechst 34580. Confocal microscopy images are representative of n = 2 biologically independent experiments. Scale bar is 10 µm (upper panel) and 2 µm (zoomed in lower panel). (K) Solutions containing 0.5 µM Atto488‐conjugated Pep19‐2.5 were prepared in the presence of increasing concentrations of recombinant human caspase‐1 and incubated overnight at 4°C under gentle agitation. Microfluidic diffusional sizing (MDS) measurements were performed at room temperature to determine the hydrodynamic radius ( R h ) of fluorescently labeled particles. Dots represent the mean ± SD of replicates ( n ≥ 3) of free peptide and peptide–protein complexes, and the black line represents the best nonlinear fit according to Equation . (L) Human recombinant caspase‐1 was incubated with the caspase‐1‐specific substrate Ac‐YVAD‐AMC at the indicated concentrations of Pep19‐2.5 or 40 µM of the caspase‐1 inhibitor VX765. Enzyme activity in relative fluorescence units (RFU) was measured every 2 min at 37°C. Representative traces are means ± SEM ( n = 2 biologically independent experiments).
    Fluorogenic Caspase 1 Substrate Ac Yvad Amc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Ac-YVAD-AMC/pmc13386142-256-1-6
    Average 94 stars, based on 1 article reviews
    fluorogenic caspase 1 substrate ac yvad amc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    MedChemExpress fluorogenic substrate
    Pre‐incubation with Pep19‐2.5 inhibits nigericin‐ and MSU crystal‐induced IL‐1β secretion. (A) Primary monocytes were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and then stimulated with 10 µM nigericin or 200 µg/mL MSU crystals for 3 h. Pep19‐2.5 was added 30 min before priming at increasing concentrations ranging from 0.4 to 18 µM. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean ± SEM ( n = 4 biologically independent experiments for nigericin, n = 2 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (B) hMDMs were primed with 1 µg/mL Pam 3 CSK 4 for 4 h and then stimulated with 5 µM nigericin for 2 h. Pep19‐2.5 was added at the indicated concentrations 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimuli‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments). One‐sample t ‐test against 100%. (C) THP‐1 macrophages were primed and stimulated as described in (A). For inhibition experiments, 18 µM Pep19‐2.5 was added 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments for nigericin, n = 3 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (D and E) THP‐1 macrophages were primed and treated with NLRP1 (D) or AIM2 (E) activators. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (F–H) Protein expression of pro‐IL‐1β (F), full‐length (G), and cleaved GSDMD (H) were analyzed by Western blot. Basal, Pam 3 CSK 4 ‐ or nigericin‐induced expression was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (I) THP‐1 macrophages were primed and stimulated after peptide incubation as described in (A). After 1 h of stimulation with nigericin, the medium was removed, and Z‐WEHD buffer was added according to the manufacturer´s protocol. Ac‐YVAD‐CHO control was subtracted, and <t>stimulus‐induced</t> <t>caspase‐1</t> activity was normalized to 100%. Mean ± SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (J) hMDMs from healthy donors were seeded in µ‐Slides VI and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Macrophages were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and stimulated with 10 µM nigericin for 1 h in the presence of fluorophore‐conjugated Rh‐Pep19‐2.5. Active caspase‐1 was stained with the caspase‐1 pseudosubstrate FLICA660‐YVAD‐FMK. Cells were washed and fixed, and nuclei were stained with Hoechst 34580. Confocal microscopy images are representative of n = 2 biologically independent experiments. Scale bar is 10 µm (upper panel) and 2 µm (zoomed in lower panel). (K) Solutions containing 0.5 µM Atto488‐conjugated Pep19‐2.5 were prepared in the presence of increasing concentrations of recombinant human caspase‐1 and incubated overnight at 4°C under gentle agitation. Microfluidic diffusional sizing (MDS) measurements were performed at room temperature to determine the hydrodynamic radius ( R h ) of fluorescently labeled particles. Dots represent the mean ± SD of replicates ( n ≥ 3) of free peptide and peptide–protein complexes, and the black line represents the best nonlinear fit according to Equation . (L) Human recombinant caspase‐1 was incubated with the caspase‐1‐specific substrate Ac‐YVAD‐AMC at the indicated concentrations of Pep19‐2.5 or 40 µM of the caspase‐1 inhibitor VX765. Enzyme activity in relative fluorescence units (RFU) was measured every 2 min at 37°C. Representative traces are means ± SEM ( n = 2 biologically independent experiments).
    Fluorogenic Substrate, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Ethylenediaminetetraacetic+acid/pm42142054-175-16-19
    Average 96 stars, based on 1 article reviews
    fluorogenic substrate - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    MedChemExpress fluorogenic substrate z fr afc
    Pre‐incubation with Pep19‐2.5 inhibits nigericin‐ and MSU crystal‐induced IL‐1β secretion. (A) Primary monocytes were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and then stimulated with 10 µM nigericin or 200 µg/mL MSU crystals for 3 h. Pep19‐2.5 was added 30 min before priming at increasing concentrations ranging from 0.4 to 18 µM. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean ± SEM ( n = 4 biologically independent experiments for nigericin, n = 2 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (B) hMDMs were primed with 1 µg/mL Pam 3 CSK 4 for 4 h and then stimulated with 5 µM nigericin for 2 h. Pep19‐2.5 was added at the indicated concentrations 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimuli‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments). One‐sample t ‐test against 100%. (C) THP‐1 macrophages were primed and stimulated as described in (A). For inhibition experiments, 18 µM Pep19‐2.5 was added 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments for nigericin, n = 3 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (D and E) THP‐1 macrophages were primed and treated with NLRP1 (D) or AIM2 (E) activators. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (F–H) Protein expression of pro‐IL‐1β (F), full‐length (G), and cleaved GSDMD (H) were analyzed by Western blot. Basal, Pam 3 CSK 4 ‐ or nigericin‐induced expression was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (I) THP‐1 macrophages were primed and stimulated after peptide incubation as described in (A). After 1 h of stimulation with nigericin, the medium was removed, and Z‐WEHD buffer was added according to the manufacturer´s protocol. Ac‐YVAD‐CHO control was subtracted, and <t>stimulus‐induced</t> <t>caspase‐1</t> activity was normalized to 100%. Mean ± SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (J) hMDMs from healthy donors were seeded in µ‐Slides VI and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Macrophages were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and stimulated with 10 µM nigericin for 1 h in the presence of fluorophore‐conjugated Rh‐Pep19‐2.5. Active caspase‐1 was stained with the caspase‐1 pseudosubstrate FLICA660‐YVAD‐FMK. Cells were washed and fixed, and nuclei were stained with Hoechst 34580. Confocal microscopy images are representative of n = 2 biologically independent experiments. Scale bar is 10 µm (upper panel) and 2 µm (zoomed in lower panel). (K) Solutions containing 0.5 µM Atto488‐conjugated Pep19‐2.5 were prepared in the presence of increasing concentrations of recombinant human caspase‐1 and incubated overnight at 4°C under gentle agitation. Microfluidic diffusional sizing (MDS) measurements were performed at room temperature to determine the hydrodynamic radius ( R h ) of fluorescently labeled particles. Dots represent the mean ± SD of replicates ( n ≥ 3) of free peptide and peptide–protein complexes, and the black line represents the best nonlinear fit according to Equation . (L) Human recombinant caspase‐1 was incubated with the caspase‐1‐specific substrate Ac‐YVAD‐AMC at the indicated concentrations of Pep19‐2.5 or 40 µM of the caspase‐1 inhibitor VX765. Enzyme activity in relative fluorescence units (RFU) was measured every 2 min at 37°C. Representative traces are means ± SEM ( n = 2 biologically independent experiments).
    Fluorogenic Substrate Z Fr Afc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorogenic+substrate/Z-Gly-Pro-Arg-AMC+hydrochloride/pmc13399510-89-18-23
    Average 94 stars, based on 1 article reviews
    fluorogenic substrate z fr afc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing Cathepsin B activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.

    Journal: bioRxiv

    Article Title: GPNMB enables lysosomal adaptation required for myelin clearance and nerve regeneration after peripheral nerve injury

    doi: 10.64898/2026.10.12.758439

    Figure Lengend Snippet: (A) Representative confocal images of NTC and GPNMB KO human iPSC-derived macrophages treated with DMSO, bafilomycin A1 (BafA1), AZD8055, or HBSS and stained for p62/SQSTM1 (green), LAMP1 (red), GPNMB (yellow), and DAPI (blue). Arrowheads indicate p62-positive structures following BafA1 treatment. Insets show higher-magnification views of the boxed regions. Scale bars, 20 μm (main panels) and 10 μm (insets). (B) High-magnification representative confocal images highlighting p62/SQSTM1 (green), LAMP1 (red), and GPNMB (yellow) positive compartments in NTC and GPNMB KO macrophages following DMSO or HBSS treatment. Under starvation conditions (HBSS), NTC macrophages exhibited a predominantly diffuse p62 staining pattern, whereas GPNMB KO macrophages retained prominent p62-positive puncta and altered intracellular p62 distribution. Scale bar, 10 μm. (C) Quantification of p62-positive area, expressed as the percentage of total cell area, in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (D-E) Quantification of mean LAMP1 fluorescence intensity per cell ( D ) and LAMP1-positive puncta per cell ( E ) in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (F–G) Quantification of p62-LAMP1 colocalization, expressed as the fraction of p62 signal colocalizing with LAMP1-positive lysosomal compartments ( F ), and GPNMB-LAMP1 colocalization, expressed as the total overlap area between GPNMB- and LAMP1-positive structures (µm²) ( G ), in GPNMB KO and NTC human iPSC-derived macrophages following 24 h treatment with DMSO, BafA1, AZD8055, or HBSS. (H) Kinetics of phagocytosis in GPNMB KO and NTC iM0 macrophages assessed by Incucyte live-cell imaging following exposure to pHrodo™-labeled Staphylococcus aureus bioparticles. Phagocytic uptake was quantified as integrated red fluorescence intensity (RCU/μm²/image) at the indicated time points. Bafilomycin A1 (BafA1), an inhibitor of lysosomal acidification, was included as a positive control for impaired lysosomal processing of internalized cargo. Individual traces represent independent wells. (I) Representative confocal images showing uptake and lysosomal processing of pHrodo-labeled myelin (green) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, bafilomycin A1 (BafA1), or AZD8055. Lysosomes were labeled with LysoTracker Red (red). Bottom panels show higher-magnification views of the boxed regions. Scale bars, 40 μm (main panels) and 10 μm (high-magnification insets). (J) Quantification of myelin-associated lysosomal signal (A.U.), defined as the association of pHrodo-labeled myelin (green) with LysoTracker-positive lysosomal compartments (red), in NTC and GPNMB KO macrophages following the indicated treatments. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (K) Quantification of LysoTracker-positive lysosomes per cell in NTC and GPNMB KO human iPSC-derived M0 following treatment with DMSO, BafA1, or AZD8055 in the presence of pHrodo-labeled myelin. Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (L) Representative confocal images showing Cathepsin B activity detected using the Magic Red Cathepsin B reporter (orange) in NTC and GPNMB KO human iPSC-derived M0 macrophages (iM0) following treatment with DMSO, LPS, bafilomycin A1 (BafA1), or myelin. Nuclei were counterstained with DAPI (blue). Scale bar, 20 μm. (M) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 2 h after probe addition. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple-comparisons test or Šidák’s multiple-comparisons test. Significance is indicated on the graphs. p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.0001.

    Article Snippet: Lysosomal proteolytic activity was assessed in iPSC-derived M0 macrophages (iM0) using the fluorogenic Magic Red Cathepsin B substrate (ImmunoChemistry Technologies), which emits red fluorescence upon cleavage by active cathepsin B in acidic intracellular compartments.

    Techniques: Confocal, Derivative Assay, Staining, Fluorescence, Live Cell Imaging, Labeling, Positive Control, Analysis, Activity Assay, Reporter Assay

    (A) Phagocytic uptake of pHrodo Red-labeled S. aureus bioparticles by human iPSC-derived M0 macrophages (iM0) treated with DMSO or bafilomycin A1 (BafA1). Phagocytic activity is presented as area under the curve (AUC) of fluorescence intensity values normalized to baseline (t = 0). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (B–C) Quantification of myelin processing in GPNMB KO and NTC iM0 macrophages following uptake of pHrodo-labeled myelin. (B) Internalized myelin quantified as total myelin-positive area per cell. (C) Lysosomal compartment size quantified as LysoTracker-positive area per cell. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. (D) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC iM0 macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 1 h after probe addition. BafA1 and CA-074 were included as controls for inhibition of lysosomal acidification and Cathepsin B activity, respectively. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. (E) Representative fluorescence images of NTC and GPNMB KO iM0 macrophages stained for Cathepsin B activity using the Magic Red reporter assay. Insets show higher-magnification views of individual cells. Scale bars, 10 μm. (F) Representative fluorescence images of NTC and GPNMB KO iPSC-derived microglia stained for p62/SQSTM1. Insets show higher-magnification views of individual cells illustrating the distribution and morphology of p62/SQSTM1-positive puncta. Scale bars, 20 μm (main images) and 10 μm (insets). Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data represent n = 2-5 independent experimental replicates. Statistical significance is denoted as * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: bioRxiv

    Article Title: GPNMB enables lysosomal adaptation required for myelin clearance and nerve regeneration after peripheral nerve injury

    doi: 10.64898/2026.10.12.758439

    Figure Lengend Snippet: (A) Phagocytic uptake of pHrodo Red-labeled S. aureus bioparticles by human iPSC-derived M0 macrophages (iM0) treated with DMSO or bafilomycin A1 (BafA1). Phagocytic activity is presented as area under the curve (AUC) of fluorescence intensity values normalized to baseline (t = 0). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple-comparisons test. (B–C) Quantification of myelin processing in GPNMB KO and NTC iM0 macrophages following uptake of pHrodo-labeled myelin. (B) Internalized myelin quantified as total myelin-positive area per cell. (C) Lysosomal compartment size quantified as LysoTracker-positive area per cell. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. (D) Quantification of lysosomal proteolytic activity in GPNMB KO and NTC iM0 macrophages under untreated conditions or following treatment with DMSO, LPS, bafilomycin A1 (BafA1), CA-074, or myelin. Cathepsin B activity was measured using the Magic Red Cathepsin B reporter assay and quantified as Magic Red-positive area per cell 1 h after probe addition. BafA1 and CA-074 were included as controls for inhibition of lysosomal acidification and Cathepsin B activity, respectively. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. (E) Representative fluorescence images of NTC and GPNMB KO iM0 macrophages stained for Cathepsin B activity using the Magic Red reporter assay. Insets show higher-magnification views of individual cells. Scale bars, 10 μm. (F) Representative fluorescence images of NTC and GPNMB KO iPSC-derived microglia stained for p62/SQSTM1. Insets show higher-magnification views of individual cells illustrating the distribution and morphology of p62/SQSTM1-positive puncta. Scale bars, 20 μm (main images) and 10 μm (insets). Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. Data represent n = 2-5 independent experimental replicates. Statistical significance is denoted as * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: Lysosomal proteolytic activity was assessed in iPSC-derived M0 macrophages (iM0) using the fluorogenic Magic Red Cathepsin B substrate (ImmunoChemistry Technologies), which emits red fluorescence upon cleavage by active cathepsin B in acidic intracellular compartments.

    Techniques: Labeling, Derivative Assay, Activity Assay, Fluorescence, Analysis, Reporter Assay, Inhibition, Staining, Morphology

    Pre‐incubation with Pep19‐2.5 inhibits nigericin‐ and MSU crystal‐induced IL‐1β secretion. (A) Primary monocytes were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and then stimulated with 10 µM nigericin or 200 µg/mL MSU crystals for 3 h. Pep19‐2.5 was added 30 min before priming at increasing concentrations ranging from 0.4 to 18 µM. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean ± SEM ( n = 4 biologically independent experiments for nigericin, n = 2 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (B) hMDMs were primed with 1 µg/mL Pam 3 CSK 4 for 4 h and then stimulated with 5 µM nigericin for 2 h. Pep19‐2.5 was added at the indicated concentrations 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimuli‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments). One‐sample t ‐test against 100%. (C) THP‐1 macrophages were primed and stimulated as described in (A). For inhibition experiments, 18 µM Pep19‐2.5 was added 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments for nigericin, n = 3 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (D and E) THP‐1 macrophages were primed and treated with NLRP1 (D) or AIM2 (E) activators. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (F–H) Protein expression of pro‐IL‐1β (F), full‐length (G), and cleaved GSDMD (H) were analyzed by Western blot. Basal, Pam 3 CSK 4 ‐ or nigericin‐induced expression was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (I) THP‐1 macrophages were primed and stimulated after peptide incubation as described in (A). After 1 h of stimulation with nigericin, the medium was removed, and Z‐WEHD buffer was added according to the manufacturer´s protocol. Ac‐YVAD‐CHO control was subtracted, and stimulus‐induced caspase‐1 activity was normalized to 100%. Mean ± SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (J) hMDMs from healthy donors were seeded in µ‐Slides VI and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Macrophages were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and stimulated with 10 µM nigericin for 1 h in the presence of fluorophore‐conjugated Rh‐Pep19‐2.5. Active caspase‐1 was stained with the caspase‐1 pseudosubstrate FLICA660‐YVAD‐FMK. Cells were washed and fixed, and nuclei were stained with Hoechst 34580. Confocal microscopy images are representative of n = 2 biologically independent experiments. Scale bar is 10 µm (upper panel) and 2 µm (zoomed in lower panel). (K) Solutions containing 0.5 µM Atto488‐conjugated Pep19‐2.5 were prepared in the presence of increasing concentrations of recombinant human caspase‐1 and incubated overnight at 4°C under gentle agitation. Microfluidic diffusional sizing (MDS) measurements were performed at room temperature to determine the hydrodynamic radius ( R h ) of fluorescently labeled particles. Dots represent the mean ± SD of replicates ( n ≥ 3) of free peptide and peptide–protein complexes, and the black line represents the best nonlinear fit according to Equation . (L) Human recombinant caspase‐1 was incubated with the caspase‐1‐specific substrate Ac‐YVAD‐AMC at the indicated concentrations of Pep19‐2.5 or 40 µM of the caspase‐1 inhibitor VX765. Enzyme activity in relative fluorescence units (RFU) was measured every 2 min at 37°C. Representative traces are means ± SEM ( n = 2 biologically independent experiments).

    Journal: Advanced Science

    Article Title: Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

    doi: 10.1002/advs.76587

    Figure Lengend Snippet: Pre‐incubation with Pep19‐2.5 inhibits nigericin‐ and MSU crystal‐induced IL‐1β secretion. (A) Primary monocytes were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and then stimulated with 10 µM nigericin or 200 µg/mL MSU crystals for 3 h. Pep19‐2.5 was added 30 min before priming at increasing concentrations ranging from 0.4 to 18 µM. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean ± SEM ( n = 4 biologically independent experiments for nigericin, n = 2 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (B) hMDMs were primed with 1 µg/mL Pam 3 CSK 4 for 4 h and then stimulated with 5 µM nigericin for 2 h. Pep19‐2.5 was added at the indicated concentrations 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimuli‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments). One‐sample t ‐test against 100%. (C) THP‐1 macrophages were primed and stimulated as described in (A). For inhibition experiments, 18 µM Pep19‐2.5 was added 30 min before priming. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 4 biologically independent experiments for nigericin, n = 3 biologically independent experiments for MSU crystals). One‐sample t ‐test against 100%. (D and E) THP‐1 macrophages were primed and treated with NLRP1 (D) or AIM2 (E) activators. Supernatants were analyzed for IL‐1β by ELISA. Stimulus‐induced IL‐1β secretion was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (F–H) Protein expression of pro‐IL‐1β (F), full‐length (G), and cleaved GSDMD (H) were analyzed by Western blot. Basal, Pam 3 CSK 4 ‐ or nigericin‐induced expression was set to 100%. Mean + SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (I) THP‐1 macrophages were primed and stimulated after peptide incubation as described in (A). After 1 h of stimulation with nigericin, the medium was removed, and Z‐WEHD buffer was added according to the manufacturer´s protocol. Ac‐YVAD‐CHO control was subtracted, and stimulus‐induced caspase‐1 activity was normalized to 100%. Mean ± SEM ( n = 3 biologically independent experiments). One‐sample t ‐test against 100%. (J) hMDMs from healthy donors were seeded in µ‐Slides VI and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Macrophages were primed with 1 µg/mL Pam 3 CSK 4 for 3 h and stimulated with 10 µM nigericin for 1 h in the presence of fluorophore‐conjugated Rh‐Pep19‐2.5. Active caspase‐1 was stained with the caspase‐1 pseudosubstrate FLICA660‐YVAD‐FMK. Cells were washed and fixed, and nuclei were stained with Hoechst 34580. Confocal microscopy images are representative of n = 2 biologically independent experiments. Scale bar is 10 µm (upper panel) and 2 µm (zoomed in lower panel). (K) Solutions containing 0.5 µM Atto488‐conjugated Pep19‐2.5 were prepared in the presence of increasing concentrations of recombinant human caspase‐1 and incubated overnight at 4°C under gentle agitation. Microfluidic diffusional sizing (MDS) measurements were performed at room temperature to determine the hydrodynamic radius ( R h ) of fluorescently labeled particles. Dots represent the mean ± SD of replicates ( n ≥ 3) of free peptide and peptide–protein complexes, and the black line represents the best nonlinear fit according to Equation . (L) Human recombinant caspase‐1 was incubated with the caspase‐1‐specific substrate Ac‐YVAD‐AMC at the indicated concentrations of Pep19‐2.5 or 40 µM of the caspase‐1 inhibitor VX765. Enzyme activity in relative fluorescence units (RFU) was measured every 2 min at 37°C. Representative traces are means ± SEM ( n = 2 biologically independent experiments).

    Article Snippet: The fluorogenic caspase‐1 substrate Ac‐YVAD‐AMC (HY‐P2717, MedChemExpress, NJ, USA) was added to a final concentration of 10 μM.

    Techniques: Incubation, Enzyme-linked Immunosorbent Assay, Inhibition, Expressing, Western Blot, Control, Activity Assay, Staining, Confocal Microscopy, Recombinant, Gentle, Labeling, Fluorescence

    Pep19‐2.5 reduces pro‐inflammatory IL‐1β response to house dust mite extract in vitro and in vivo. (A–E) Human macrophages from heathy donors were seeded in serum‐free Opti‐MEM medium and stimulated without priming with the indicated doses of house dust mite (HDM) extract for 24 h at 37°C (A) alone, in the presence of (B) the NLRP3 inhibitor MCC950 (10 µM), (C) the TLR4 antagonist eritoran (1 µg/mL), or (D–F) Pep19‐2.5. IL‐1β release was determined from cell‐free supernatants by ELISA. Data shown in (A) mean + SD of duplicate analyses and are representative for n = 7 independent donors. Data in (B–E) were normalized to 100% for HDM in the absence of inhibitors and are shown as mean + SEM of (B, C, E, F): n = 5 and (D): n = 3 independent experiments with cells from different healthy donors. Statistical significance against HDM alone was analyzed by a two‐sided t ‐test. (G) Treatment protocol for HDM‐induced allergic asthma mouse model. (H) Airway resistance in response to methacholine inhalation, (I) inflammatory cell infiltrate volume in lung tissue per epithelial basal membrane (b.m.) area, and (J) numbers of eosinophils on day 14 in bronchoalveolar lavage (BAL) fluid of healthy (PBS), asthmatic (HDM), or Pep19‐2.5‐treated mice (HDM + peptide), n = 10 mice per group. (K–O) Cytokine levels in BAL fluid were assessed by MSD U‐Plex assays. (P) Caspase‐1 mRNA expression in BAL cells and (Q) caspase‐1 protein determined by Western blot. (R) Final body weight on day 14 of the treatment protocol. Results are presented as mean values ± SEM. Statistical significance was assessed using ordinary one‐way ANOVA and Tukey´s multiple comparison post hoc analyses.

    Journal: Advanced Science

    Article Title: Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

    doi: 10.1002/advs.76587

    Figure Lengend Snippet: Pep19‐2.5 reduces pro‐inflammatory IL‐1β response to house dust mite extract in vitro and in vivo. (A–E) Human macrophages from heathy donors were seeded in serum‐free Opti‐MEM medium and stimulated without priming with the indicated doses of house dust mite (HDM) extract for 24 h at 37°C (A) alone, in the presence of (B) the NLRP3 inhibitor MCC950 (10 µM), (C) the TLR4 antagonist eritoran (1 µg/mL), or (D–F) Pep19‐2.5. IL‐1β release was determined from cell‐free supernatants by ELISA. Data shown in (A) mean + SD of duplicate analyses and are representative for n = 7 independent donors. Data in (B–E) were normalized to 100% for HDM in the absence of inhibitors and are shown as mean + SEM of (B, C, E, F): n = 5 and (D): n = 3 independent experiments with cells from different healthy donors. Statistical significance against HDM alone was analyzed by a two‐sided t ‐test. (G) Treatment protocol for HDM‐induced allergic asthma mouse model. (H) Airway resistance in response to methacholine inhalation, (I) inflammatory cell infiltrate volume in lung tissue per epithelial basal membrane (b.m.) area, and (J) numbers of eosinophils on day 14 in bronchoalveolar lavage (BAL) fluid of healthy (PBS), asthmatic (HDM), or Pep19‐2.5‐treated mice (HDM + peptide), n = 10 mice per group. (K–O) Cytokine levels in BAL fluid were assessed by MSD U‐Plex assays. (P) Caspase‐1 mRNA expression in BAL cells and (Q) caspase‐1 protein determined by Western blot. (R) Final body weight on day 14 of the treatment protocol. Results are presented as mean values ± SEM. Statistical significance was assessed using ordinary one‐way ANOVA and Tukey´s multiple comparison post hoc analyses.

    Article Snippet: The fluorogenic caspase‐1 substrate Ac‐YVAD‐AMC (HY‐P2717, MedChemExpress, NJ, USA) was added to a final concentration of 10 μM.

    Techniques: In Vitro, In Vivo, Enzyme-linked Immunosorbent Assay, Membrane, Expressing, Western Blot, Comparison